A MMP derived versican neo-epitope is elevated in plasma from patients with atherosclerotic heart disease

作者：Barascuk Natasha; Genovese Federica^*; Larsen Lise; Byrjalsen Inger; Zheng Qinlong; Sun Shu; Ho**ond Susanne; Poulsen Tina S; Diederichsen Axel; Jensen Jesper M; Mickley Hans; Register Thomas C; Rasmussen Lars M; Leeming Diana J; Christiansen Claus; Karsdal Morten A

来源：International Journal of Clinical and Experimental Medicine, 2013, 6(3): 174-184.

• Versican
• acute coronary syndrome
• atherosclerosis
• biomarker
• matrix
• remodeling
• neo-epitope

Extracellular matrix remodelling is a prerequisite for plaque rupture in atherosclerotic lesion. Versican, an extracellular matrix proteoglycan present in normal and atherosclerotic arteries is a substrate for matrix metalloproteinases (MMPs) present in macrophage rich areas. The aim of the current study was to develop an immunoassay to detect a specific MMP-12 derived versican degradation fragment (VCANM) and assess its potential as a biomarker for extracellular matrix remodelling in atherosclerosis. A mouse monoclonal antibody raised against VCANM was used for the development of a competitive ELISA for detection of the fragment in plasma. VCANM was measured in plasma of patients with different levels of heart diseases. Patients experiencing I) acute coronary syndrome, II) stable ischemic heart disease and III) demonstrating high levels of coronary calcium deposits had significantly higher plasma levels of VCANM compared to a control group of individuals with no detectable coronary calcium deposits. VCANM was also detected by immunohistochemistry in coronary artery sections of patients with different degrees of atherosclerosis. VCANM ability to separate patients with atherosclerotic diseases from healthy individuals suggested VCANM as a potential biomarker for the pathological arterial matrix remodelling associated with atherosclerosis.

• 出版日期2013